Article

Tecnis multifocal safe and effective in hyperopia and presbyopia

The Tecnis multifocal intraocular lens (MIOL) is safe and efficacious for refractive lensectomy in hyperopia and presbyopia, according to Frank Goes, Belgium.

The Tecnis multifocal intraocular lens (MIOL) is safe and efficacious for refractive lensectomy in hyperopia and presbyopia, according to Frank Goes, Belgium.

At a private outpatient centre in Antwerp, Belgium, 94 presbyopic hyperopic eyes of 47 subjects were implanted with the Tecnis MIOL. Outcomes were recorded at six months from baseline.

The lens demonstrated two clearly defined focal points and MTF results, independent of pupil size. Uncorrected visual acuity (UCVA) improved from 20/100 preoperatively to 20/23 postoperatively. Best corrected visual acuity (BCVA) improved from 20/25 to 20/20. All but four eyes could read J1 monocular with eventual distance correction and 44 out of the 47 subjects could read J3 at intermediate PC distance (22 inches) with eventual distance correction. No eyes lost any lines of vision and 44 subjects were completely spectacle free. A questionnaire found that the satisfaction degree was either excellent (39 patients; 83%) or good (8 patients; 17%).

Goes concluded that the Tecnis lens is able to offer good visual performance, independent of pupil size, as well as being both safe and efficient in this patient population.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.